Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
Repertoire Immune Medicines has dosed the first participant in a Phase 1/2 trial of RPTR-1-201, a T cell-targeted immune medicine for advanced solid tumors. The trial will evaluate the safety, tolerability, and antitumor activity of RPTR-1-201 as monotherapy and in combination with an anti-PD-1 therapy.
Repertoire Immune Medicines has initiated a Phase 1/2 clinical trial of RPTR-1-201, a novel TCR bispecific therapy for advanced solid tumors. The trial is being conducted at multiple sites in the US and Europe. RPTR-1-201 is designed to direct a patient's T cells toward a shared, tumor-selective target. In preclinical studies, it demonstrated potent killing of tumors and a favorable safety profile. The trial will evaluate RPTR-1-201's safety, tolerability, and antitumor activity as monotherapy and in combination with an anti-PD-1 monoclonal antibody. Enrollment is ongoing at sites in the US and Europe.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.